Challenges of Treating Acute Heart Failure in Patients with Chronic Obstructive Pulmonary Disease.

Autor: Čelutkienė J; Clinic of Cardiac and Vascular Diseases, Vilnius University, Vilnius, Lithuania.; Centre of Cardiology and Angiology, Vilnius University Hospital Santariškių Klinikos, Vilnius, Lithuania., Balčiūnas M; Clinic of Cardiac and Vascular Diseases, Vilnius University, Vilnius, Lithuania.; Department of Cardiothoracic Anaesthesia and Intensive Care, Papworth Hospital NHS Foundation Trust, Cambridge, UK., Kablučko D; Centre of Cardiology and Angiology, Vilnius University Hospital Santariškių Klinikos, Vilnius, Lithuania., Vaitkevičiūtė L; Emergency Department, Vilnius University Hospital Santariškių Klinikos, Vilnius, Lithuania.; Clinic of Internal Disease, Family Medicine and Oncology, Vilnius University, Vilnius, Lithuania., Blaščiuk J; Emergency Department, Vilnius University Hospital Santariškių Klinikos, Vilnius, Lithuania., Danila E; Clinic of Infectious and Chest Diseases, Dermatovenereology and Allergology, Vilnius University, Vilnius, Lithuania.; Vilnius University Hospital Santariškių Klinikos, Centre of Pulmonology and Allergology, Vilnius, Lithuania.
Jazyk: angličtina
Zdroj: Cardiac failure review [Card Fail Rev] 2017 Apr; Vol. 3 (1), pp. 56-61.
DOI: 10.15420/cfr.2016:23:2
Abstrakt: Heart failure (HF) and chronic obstructive pulmonary disease (COPD) comorbidity poses substantial diagnostic and therapeutic challenges in acute care settings. The specific role of pulmonary comorbidity in the treatment and outcomes of cardiovascular disease patients was not addressed in any short- or long-term prospective study. Both HF and COPD can be interpreted as systemic disorders associated with low-grade inflammation, endothelial dysfunction, vascular remodelling and skeletal muscle atrophy. HF is regularly treated as a broader cardiopulmonary syndrome utilising acute respiratory therapy. Based on observational data and clinical expertise, a management strategy of concurrent HF and COPD in acute settings is suggested. Concomitant use of beta 2 -agonists and beta-blockers in a comorbid cardiopulmonary condition seems to be safe and effective.
Competing Interests: Disclosure: JC and MB were supported by a grant from the Research Council of Lithuania MIP-049/2015. The remaining authors have no conflicts of interest to declare.
Databáze: MEDLINE
Externí odkaz: